Zoetis

ZTSPre-clinical

Zoetis operates as the leading global animal health company, spun off from Pfizer in 2013. The company focuses on discovering, developing, manufacturing, and commercializing animal health medicines, vaccines, and diagnostic products for both livestock and companion animals. With operations in more than 100 countries, Zoetis serves the critical need for animal protein production and pet health care globally.

Market Cap

$48.8B

Employees

11,000-13,000

Focus

Biotech

ZTS · Stock Price

USD 115.6773.76 (-38.94%)

Historical price data

AI Company Overview

Technology Platform

Zoetis operates integrated platforms for animal health including biologics manufacturing, vaccine development, pharmaceutical formulations, and digital health solutions for livestock and companion animals.

Funding History

Total raised: $2.2B

IPO$2.2BPfizerFeb 1, 2013

Opportunities

Zoetis is positioned to capitalize on growing global protein demand, premiumization of pet care, and digital transformation of animal health through geographic expansion and innovative product development.

Emerging markets and precision animal health represent significant growth vectors.

Risk Factors

Key risks include regulatory changes affecting antibiotic use, competitive pressure from biosimilars, economic sensitivity impacting livestock production and pet spending, and potential supply chain disruptions affecting manufacturing operations.

Competitive Landscape

Zoetis leads the global animal health market ahead of Boehringer Ingelheim Animal Health, Merck Animal Health, and Elanco. The company differentiates through its scale, diversified portfolio, R&D capabilities, and established veterinary relationships across both livestock and companion animal segments.

Publications

Patents